James B. Rebitzer and Robert S. Rebitzer

BioTech

Shortages of generic drugs can’t be blamed solely on group purchasing organizations

The Hatch-Waxman Act of 1984, which gave rise to the modern generic drug market, was one of the most significant cost-reducing policy innovations of the

James B. Rebitzer and Robert S. Rebitzer April 25, 2024

BioTech

Patent buyouts could spur vital innovation in antibiotics, vaccines, and other medical fields

The announcement by the Center for Medicare and Medicaid Services that ten drugs will be subject to price negotiation under the Inflation Adjustment Act has

James B. Rebitzer and Robert S. Rebitzer November 14, 2023

BioTech

What the hospital-at-home movement tells us about igniting innovation in health care

As a health care economist who studies innovation, and as a management consultant who helps health systems and insurers adopt new technologies, we have had

James B. Rebitzer and Robert S. Rebitzer August 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

James B. Rebitzer and Robert S. Rebitzer

Shortages of generic drugs can’t be blamed solely on group purchasing organizations

Patent buyouts could spur vital innovation in antibiotics, vaccines, and other medical fields

What the hospital-at-home movement tells us about igniting innovation in health care

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe